Researchers have found that two treatments for Chronic Fatigue Syndrome have long term benefits for people affected by the condition.
The team from Oxford University, King’s College London and Queen Mary University of London were following up patients who took part in a study published in 2011, funded by the Medical Research Council. In that study they looked at four potential treatments for Chronic Fatigue Syndrome (CFS) and found that cognitive behavioural therapy
(CBT) and graded exercise therapy (GET) achieved better outcomes than standard medical care (SMC) and adaptive pacing therapy (APT) at one year.
In this study they contacted the people who took part in the original study to find out how they were fairing two and a half years after starting the treatments.
Three quarters of the original trial participants took part in the follow up. It showed that the improvements in fatigue and physical functioning seen at one year in the trial with CBT and GET were maintained in the long-term.
Professor Michael Sharpe from the University of Oxford said: 'The finding that participants who had cognitive behavioural therapy and graded exercise therapy had maintained their improvement over 2 years after entering the trial, tells us that these treatment can improve the long-term health of people with CFS.'
The team also found that participants who originally had CBT or GET were less likely to have sought additional therapy after the trial than those who originally had standard medical care alone or APT.
Dr Kimberley Goldsmith from the Institute of Psychiatry, Psychology & Neuroscience at King’s College London said: 'We found that participants who had originally been given SMC or APT appeared to be doing as well as those who had CBT or GET in the longer term. However as many had received CBT or GET after the trial, it does not tell us that these treatments have as good a long term outcome as CBT and GET.'
There were no significant differences between the four original treatment groups in the number reporting a long-term deterioration in their general health (around 1 in 10 of each group). This showed that there was no evidence that those who received CBT and GET were more likely to worsen in the long term.
Professor Peter White from Queen Mary University of London said: 'Finding no significant differences in the proportions getting worse over time is a reassurance for those who worry that some of these treatments might make things worse. But it is also a reminder that these treatments do not help everybody, and more research is needed into finding other treatments that help.'
See abstract of study at: http://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366%2815...

FORT LAUDERDALE-DAVIE, Fla. – Nova Southeastern University (NSU) Executive Vice President and Provost Ralph V. Rogers Jr., Ph.D., recently presented Nancy Klimas, M.D., with the 5th Annual Provost’s Research and Scholarship Award.
The purpose of the award is to recognize a faculty member who has demonstrated significant achievement in support of NSU’s mission to foster scholarship, intellectual inquiry, and academic excellence.
Research and scholarship are two of NSU’s eight core values, and excellence in these areas enhances education, patient care, and public service, and develops superior scholarship.
“We are proud of Dr. Klimas for exemplifying NSU’s Core Values through her groundbreaking research in the field of neuro-immune medicine,”
said Dr. Rogers.
The announcement was made at the External Funding Recognition Reception, hosted by Gary S. Margules, Sc.D., vice president of NSU’s Office of Research and Technology Transfer, at which faculty members from all disciplines across the university are recognized for their commitment to advancing their fields of study.
 “I am humbled by this honor and accept this award on behalf of my team of world-class researchers in the hopes that our discoveries will make a true difference in the lives of those facing neuro-immune disorders,” said Dr. Klimas. “I am proud to be a part of the NSU family and work with researchers in a diverse array of fields.”
Dr. Klimas has achieved international recognition for her research and clinical efforts in multi-symptom disorders, chronic fatigue syndrome and myalgic encephalomyelitis (CFS/ME), Gulf War illness (GWI), and fibromyalgia. Among many other honors, Dr. Klimas was the recipient of the 2014 Perpich Award by the International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (IACFS/ME) for distinguished community service. She also was featured as a “Woman to Watch” on WFOR CBS 4.
She currently serves as director of NSU’s Institute for Neuro-Immune Medicine, professor of medicine, and chair of the Department of Clinical Immunology at NSU’s College of Osteopathic Medicine. She is also professor emerita at the University of Miami School of Medicine, director of clinical immunology research at the Miami Veterans Affairs Medical Center (VAMC) and leads the GWI and ME/CFS clinical and research program at the Miami VA.
Dr. Klimas is a diplomate of the American Board of Internal Medicine and a diplomate in diagnostic laboratory immunology. She is a past president of the IACFS/ME and is also a member of the VA Research Advisory Committee for GWI, the National Institutes of Health’s (NIH) P2P CFS committee, and served on the Institute of Medicine’s ME/CFS review panel.
Klimas has advised three U.S. secretaries of health and human services during her repeated service on the U.S. Department of Health and Human Services CFS Advisory Committee. She is currently funded by the VA, Department of Defense and NIH to study these complex disorders using a systems biology approach with a strong focus on illness models that lead to therapeutic targets and clinical trials.

​Two of the nation’s leading experts on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)—Bateman Horne Center Chief Medical Officer Dr. Lucinda Bateman, MD and Researcher Dr. Suzanne D. Vernon, PhD—announce their partnership to quantify diagnostic criteria recommended by the Institute of Medicine (IOM) of the National Academy of Sciences. 
Dr. Bateman was a member of the IOM Committee that penned the 304-page report Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Released in February 2015, the report recommended diagnostic criteria for the main disease symptoms: fatigue that impairs normal activity, post-exertional malaise, unrefreshing sleep, cognitive impairment and orthostatic intolerance.
“If we are ever to mainstream medical care for the millions who suffer terribly from this disease,” says Dr. Bateman, “there must be diagnostic tests. Dr. Vernon’s experience in identifying biomarkers, establishing biobanks and cost-effectively gathering large amounts of real-life, real-time data will close in on this reality.”
Dr. Vernon will spend the next several months finalizing the research initiative’s design with data collection and analysis continuing into 2016 and beyond. “I’ve had great success recruiting innovative partners and rock star scientists into ME/CFS research,” says Dr. Vernon. “Now Dr. Bateman and I will establish Bateman Horne Center as a center of excellence for research and clinical care.”